Seeking Alpha

Jolk's  Instablog

Jolk
Send Message
Learning quickly about how to invest.
  • Vascepa Lowers Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) 0 comments
    May 20, 2013 10:43 PM | about stocks: AMRN

    Vascepa, when combined with statin, reduced lp-PLA2 by 19% over statin alone at a 4g/day dose for a duration of 12 weeks in the ANCHOR population (200-499mg/dL trigs).

    Familiarize yourself with lp-PLA2 by watching this video: www.youtube.com/watch

    Listen to these insightful comments from the 2007 American Heart Association Scientific Sessions entitled "Advances in the Detection of Rupture-Prone Plaque: The Role of Lp-PLA2 in Cardiovascular Risk Assessment.": www.youtube.com/watch

    Keep in mind the information on risk of stroke.

    Let's look at a testing center's summary of lp-PLA2: www.questdiagnostics.com/testcenter/testguide.action

    Clinical Background

    Traditional markers of lipidemia identify only about half of the individuals at risk of cardiovascular disease (NYSE:CVD).1 Atherosclerosis is now recognized as an inflammatory disease, and inflammatory markers, most notably high-sensitivity C-reactive protein (hs-CRP), have been shown to identify additional individuals who are at risk. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is another marker of vascular inflammation, and because it is not associated with systemic inflammation it is more vascular-specific than is CRP.2 It is produced by macrophages and other inflammatory cells and is found in atherosclerotic lesions.

    Increased blood levels of Lp-PLA2 have been linked to increased risk for: 1) cerebral thrombosis,3 2)
    first4 and recurrent5 coronary events, 3) adverse prognosis after acute coronary syndrome,6 and 4) CVD associated with metabolic syndrome7 or type 2 diabetes mellitus.8 Evidence from more than 25 prospective studies has shown an approximate doubling of risk for coronary artery disease (NYSEARCA:CAD), CVD, and stroke when comparing Lp-PLA2 values in the top quintile versus the bottom quintile.2 The predictive value typically remains after adjustment for LDL-cholesterol and other established CVD risk factors.2

    Now let's look at an article from the American Journal of Cardiology, Volume 101, Issue 12 Supplement, 16 June 2008, Pages S41-S50 www.sciencedirect.com/science/article/pii/S0002914908007157

    From Figure 2:

    Figure 2. Elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) is consistently associated with a doubling of risk for cardiovascular disease (CVD). Published prospective epidemiologic studies show the association of elevated Lp-PLA2 (top quantile vs bottom quantile) with cardiovascular risk. A fairly consistent near doubling of risk is associated with elevated Lp-PLA2. Results are fully adjusted for traditional risk factors, lipids, and often for body mass index and high-sensitivity C-reactive protein

    So we have a treatment with adverse effects similar to placebo that will lower an important, specific cardiovascular risk marker. This is one factor into why Vascepa looks to be a promising option for those at risk for any major, adverse cardiovascular event.

    Now back to stroke risk, in the JELIS study, where patients were given 1.8 grams EPA a day with statin vs. statin and placebo, those patients with a prior history of stroke, saw a 20% relative reduction in recurrent stroke in the EPA/statin group vs. the statin and placebo group. www.ncbi.nlm.nih.gov/pubmed/18451347

    In the secondary prevention subgroup, stroke occurred in 48 (10.5%) of 457 no EPA group and in 33 (6.8%) of 485 EPA group, showing a 20% relative reduction in recurrent stroke in the EPA group (Hazard Ratio, 0.80; 95% confidence interval, 0.64 to 0.997).

    CONCLUSIONS:

    Administration of highly purified EPA appeared to reduce the risk of recurrent stroke in a Japanese population of hypercholesterolemic patients receiving low-dose statin therapy.

    lp-PLA2 is associated with unstable or ruptured plaques, just how does EPA (Vascepa) involve itself in improving the actual structural morphology of these plaques? Next time.

    Disclosure: I am long AMRN.

Back To Jolk's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.